Insiders, IPOs

Vant commander Ramaswamy heads back to Nasdaq with a $150M pitch — are investors ready to forgive Axovant?

Love him or hate him, and there are plenty of people in both camps now, Vivek Ramaswamy is never boring.

On Friday Ramaswamy’s Dermavant — part of the growing Roivant camp he runs — inked a $330 million deal to gain the worldwide rights to a Phase III-ready psoriasis drug from GlaxoSmithKline. That was two days after Ramaswamy recruited Genentech vet Myrtle Potter to come in as a Roivant operating chair for the group of biotechs he has ramped up. He also launched his 12th company — Immunovant — just days after reorganizing the company, which now collectively has more than 600 staffers.

And here’s something new: He capped the week by handing over an S-1 for Urovant, his urology company in search of a $150 million-plus IPO to cover the cost of their Phase III program.

Endpoints Insider

Endpoints Enterprise

Unlock this article along with other benefits by subscribing to one of our paid plans.
Already a subscriber? Log in now
← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 35,300+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->